CLEVELAND BIOLABS
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has vario… Read more
CLEVELAND BIOLABS (7CB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CLEVELAND BIOLABS (7CB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CLEVELAND BIOLABS - Net Assets Trend (None–None)
This chart illustrates how CLEVELAND BIOLABS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CLEVELAND BIOLABS (None–None)
The table below shows the annual net assets of CLEVELAND BIOLABS from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CLEVELAND BIOLABS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CLEVELAND BIOLABS Competitors by Market Cap
The table below lists competitors of CLEVELAND BIOLABS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TOTAL PETROLEUM GHANA LTD
GSE:TOTAL
|
$25.05K |
|
Pulse Evolution Corp
PINK:PLFX
|
$25.06K |
|
PRECIOUS METAL + MIN.TR.
F:5Z5
|
$25.06K |
|
254160
KO:254160
|
$25.06K |
|
NIPPON SHEET GLASS - Dusseldorf Stock Exchang
DU:NI9
|
$25.02K |
|
RAISIO -V-
MU:RATV
|
$24.98K |
|
Pyung Hwa Holdings Co. Ltd.
KQ:010770
|
$24.98K |
|
PeakBirch Logic Inc
PINK:PKBFF
|
$24.98K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CLEVELAND BIOLABS's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CLEVELAND BIOLABS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CLEVELAND BIOLABS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CLEVELAND BIOLABS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CLEVELAND BIOLABS (7CB) | €- | N/A | N/A | $25.03K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |